Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	281.93	37.8	39.55	298.17	89.96	81.47
Short-Term Investments	56.88	50.55	62.88	29.31	83.51	211.47
Cash & Short-Term Investments	338.8	88.35	102.43	327.48	173.47	292.94
Cash Growth	252.63%	-13.74%	-68.72%	88.79%	-40.78%	4.31%
Accounts Receivable	21.92	18.44	17.47	16.79	14.07	15.87
Other Receivables	-	50	-	-	-	53.8
Receivables	21.92	68.44	17.47	16.79	14.07	69.67
Prepaid Expenses	5.57	4.28	13.64	9.2	18.81	30.73
Other Current Assets	-	-	-	-	43.53	-
Total Current Assets	366.29	161.07	133.54	353.46	249.87	393.34
Property, Plant & Equipment	33.13	35.77	45.36	52	53.35	59.68
Long-Term Investments	-	-	-	-	-	12.75
Other Long-Term Assets	26.61	157.32	203.1	201.94	71.6	3.28
Total Assets	426.04	354.16	382	607.4	374.82	469.06
Accounts Payable	1.68	2.24	1.52	1.55	3.1	6.78
Accrued Expenses	15.37	13.28	12.83	20.41	37.95	76.07
Current Portion of Long-Term Debt	-	-	-	-	16.94	19.33
Current Portion of Leases	10.9	10.71	3.92	6.75	0.5	9.87
Current Income Taxes Payable	26.7	5.85	-	-	-	-
Current Unearned Revenue	-	-	-	-	0.1	11.52
Other Current Liabilities	-	-	6.49	-	-	-
Total Current Liabilities	54.63	32.09	24.77	28.72	58.59	123.57
Long-Term Debt	-	-	-	-	599.39	599.84
Long-Term Leases	35.56	39.11	45.24	45.41	52.68	47.22
Long-Term Unearned Revenue	-	-	-	0.19	0.31	0.35
Other Long-Term Liabilities	110.99	107.42	99	91.29	2.42	1.83
Total Liabilities	201.19	178.62	169	165.6	713.39	772.81
Common Stock	0	-	-	0	0	0
Additional Paid-In Capital	1,149	1,141	1,122	1,296	1,387	1,223
Retained Earnings	-924.27	-965.52	-909.1	-853.91	-1,726	-1,527
Comprehensive Income & Other	-0.01	0.01	-0.07	-0.02	-	0.05
Shareholders' Equity	224.85	175.55	213	441.8	-338.57	-303.75
Total Liabilities & Equity	426.04	354.16	382	607.4	374.82	469.06
Total Debt	46.46	49.82	49.16	52.16	669.52	676.26
Net Cash (Debt)	292.35	38.53	53.27	275.32	-496.05	-383.32
Net Cash Growth	491.58%	-27.67%	-80.65%	-	-	-
Net Cash Per Share	5.85	0.79	0.96	3.74	-7.14	-6.15
Filing Date Shares Outstanding	50.36	49.47	48.16	62.86	74.7	64.33
Total Common Shares Outstanding	50.36	49.47	48.09	65.23	74.44	64.33
Working Capital	311.66	128.98	108.77	324.75	191.28	269.77
Book Value Per Share	4.46	3.55	4.43	6.77	-4.55	-4.72
Tangible Book Value	224.85	175.55	213	441.8	-338.57	-303.75
Tangible Book Value Per Share	4.46	3.55	4.43	6.77	-4.55	-4.72
Machinery	-	3.74	3.68	19.04	26.03	35.88
Leasehold Improvements	-	25.32	26.21	24.58	24.05	24.28

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q